![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amarin Corp | LSE:AMRN | London | Ordinary Share | GB00B29VL935 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 92.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:6263Y Amarin Corporation Plc 19 June 2007 AMARIN CORPORATION PLC LONDON, United Kingdom, June 19, 2007, Amarin Corporation plc ("Amarin" or "Company") announces that it is sending to its shareholders today the following documentation in relation to its Annual General Meeting to be held at 7 Curzon Street, Mayfair, London W1J 5HG on July 19, 2007, a Notice of the Annual General Meeting, a Proxy Form, a copy of its Annual Report for the year ended December 31, 2006 and a letter regarding the potential future communication of shareholder information by electronic means. A copy of each of these documents is available on the Company's website at http://www.amarincorp.com/investor_relations/investor_relations.424.html About Amarin Amarin is committed to improving the lives of patients suffering from diseases of the central nervous system. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs. Amarin's core development pipeline includes, in addition to Miraxion for several therapeutic indications, four other key development programs in Parkinson's disease, epilepsy seizures, memory and cognition and our proprietary pre-clinical combinatorial lipid program. Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively. For press releases and other corporate information, visit the Amarin website at http://www.amarincorp.com. Information on our website does not form part of this press release. Contacts: Amarin +44 (0) 207 907 2442 Rick Stewart, Chief Executive Officer Alan Cooke, President and Chief Financial Officer investor.relations@amarincorp.com Investors: Lippert/Heilshorn & Associates, Inc. Anne Marie Fields , +1 212 838 3777 Bruce Voss, +1 310 691 7100 Media: Powerscourt +44 (0) 207 250 1446 Rory Godson Ends. This information is provided by RNS The company news service from the London Stock Exchange END NOAUKSURBKRNAAR
1 Year Amarin Chart |
1 Month Amarin Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions